Compare
Eloxx Pharmaceuticals, Inc. vs Vaxart, Inc. vs Repligen Corp vs Champions Oncology, Inc.
| Latest fiscal year | Eloxx Pharmaceuticals, Inc. ELOX | Vaxart, Inc. VXRT | Repligen Corp RGEN | Champions Oncology, Inc. CSBR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-04-30 |
| Revenue | $0 | $237.26M | $738.26M | $59.42M |
| Revenue growth (YoY) | -100.0% | +726.7% | +16.4% | +4.4% |
| Gross margin | n/a | n/a | 52.3% (computed) | 48.0% (computed) |
| Operating margin | n/a | 7.6% | 7.5% | -1.9% |
| Net margin | n/a | 6.9% | 6.6% | -2.0% |
| Net income | -$6.00M | $16.33M | $48.89M | -$1.18M |
| EPS (Diluted) | -$0.49 | $0.07 | $0.86 | -$0.08 |
| Operating cash flow | -$6.33M | $7.71M | $117.42M | -$4.47M |
| Free cash flow | n/a | $7.57M | $93.90M | -$5.04M |
| Cash & equivalents | $4.79M | n/a | $566.02M | n/a |
| Total assets | $5.27M | $186.08M | $2.95B | $26.99M |
| Total liabilities | $17.18M | $98.28M | $843.57M | $22.92M |
| Shareholders' equity | -$11.91M | $87.80M | $2.11B | $3.94M |
| Return on year-end equity | n/a | 18.6% | 2.3% | -29.8% |
| Shares outstanding | 4.79M | 240.49M | 56.33M | 13.89M |
Revenue, most recent five fiscal years
| Fiscal year | Eloxx Pharmaceuticals, Inc. | Vaxart, Inc. | Repligen Corp | Champions Oncology, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $237.26M Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $59.42M Ended 2026-04-30 |
| 1 year earlier | $6.36M Ended 2024-12-31 | $28.70M Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $56.94M Ended 2025-04-30 |
| 2 years earlier | $0 Ended 2023-12-31 | $7.38M Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $50.16M Ended 2024-04-30 |
| 3 years earlier | n/a | $107.0K Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $53.87M Ended 2023-04-30 |
| 4 years earlier | n/a | $892.0K Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $49.11M Ended 2022-04-30 |